Skip to main content

Table 2 Number of patients with C-level disease activity at study entry in each BILAG body system

From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

Body system

Number of patients

Contributing signs/symptoms* (number of patients)

I. General/Constitutional

11

Fatigue/malaise/lethargy (10)

  

Anorexia/nausea/vomiting (1)

  

Lymphadenopathy/splenomegaly (1)

  

Pyrexia (documented) (1)

II. Mucocutaneous

1

Mild alopecia (1)

III. Neurological

10

Episodic migrainous headaches (8)

  

Severe, unremitting headache (2)

IV Musculoskeletal

11

Arthralgia (10)

  

Myalgia (9)

  

Improving arthritis (1)

V. CV/Respiratory

2

Dyspnea (1)

  

Pleuropericardial pain (1)

VI. Vasculitis

4

Raynaud's (3)

  

Livido reticularis (1)

VII. Renal

4

Mild/stable proteinuria (4)

VIII. Hematology

11

Lymphocytopenia (< 1500 cells/μl) (10)

  

Evidence of circulating anticoagulant (1)

  

Decreased platelets (< 150,000/μl) (1)

  1. *Signs and symptoms that contributed to the C-level disease activity according to BILAG rules.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us